BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status

Wei Qi Li; Kawakami, Kazuyuki; Ruszkiewicz, Andrew; Bennett, Graeme; Moore, James; Iacopetta, Barry
January 2006
Molecular Cancer;2006, Vol. 5, p1
Academic Journal
Background: BRAF is a member of RAF family of serine/threonine kinases and mediates cellular responses to growth signals through the RAS-RAF-MAP kinase pathway. Activating mutations in BRAF have recently been found in about 10% of colorectal cancers, with the vast majority being a V600E hotspot mutation. The aim of the present study was to evaluate the clinical, pathological and molecular phenotype of colorectal tumors with BRAF mutations. Results: Mutations in BRAF were identified in 8% (23/275) of colorectal cancers. They were 5-10- fold more frequent in tumors with infiltrating lymphocytes, location in the proximal colon, poor histological grade and mucinous appearance (P < 0.002 for each). Tumors with BRAF mutation were also 10-fold more likely to show microsatellite instability and frequent DNA methylation (P < 0.0001) compared to tumors without this mutation. The characteristic morphological features of tumors with BRAF mutation (infiltrating lymphocytes, poor grade, mucinous) remained after stratification according to microsatellite instability and methylator phenotypes. Mutations in BRAF were mutually exclusive with mutations in KRAS but showed no clear association with the presence of TP53 mutation. Conclusion: BRAF mutation identifies a colorectal cancer subgroup with distinctive phenotypic properties independent of microsatellite instability status and thus could be a valuable marker for studies into the clinical properties of these tumors.


Related Articles

  • Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine. Shen, Yinchen; Wang, Jianfei; Han, Xiaohong; Yang, Hongying; Wang, Shuai; Lin, Dongmei; Shi, Yuankai // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti- epidermal growth factor receptor (EGFR) antibody therapies. However, some patients with KRAS wild-type tumors still do not respond, so other downstream mutations in BRAF, PIK3CA and NRAS should be...

  • The Detection of the Methylated Wif-1 Gene Is More Accurate than a Fecal Occult Blood Test for Colorectal Cancer Screening. Amiot, Aurelien; Mansour, Hicham; Baumgaertner, Isabelle; Delchier, Jean-Charles; Tournigand, Christophe; Furet, Jean-Pierre; Carrau, Jean-Pierre; Canoui-Poitrine, Florence; Sobhani, Iradj // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Background: The clinical benefit of guaiac fecal occult blood tests (FOBT) is now well established for colorectal cancer screening. Growing evidence has demonstrated that epigenetic modifications and fecal microbiota changes, also known as dysbiosis, are associated with CRC pathogenesis and...

  • KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients. López, Susana Olmedillas; García-Olmo, Dolores C.; García-Arranz, Mariano; Guadalajara, Héctor; Pastor, Carlos; García-Olmo, Damián // International Journal of Molecular Sciences;2016, Vol. 17 Issue 4, p484 

    KRAS mutations are responsible for resistance to anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer patients. These mutations sometimes appear once treatment has started. Detection of KRAS mutations in circulating cell-free DNA in plasma ("liquid biopsy") by droplet...

  • The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis. Frouws, Martine A.; Reimers, Marlies S.; Swets, Marloes; Bastiaannet, Esther; Prinse, Bianca; van Eijk, Ronald; Lemmens, Valery E. P. P.; van Herk-Sukel, Myrthe P. P.; van Wezel, Tom; Kuppen, Peter J. K.; Morreau, Hans; van de Velde, Cornelis J. H.; Liefers, Gerrit-Jan // PLoS ONE;1/26/2017, Vol. 12 Issue 1, p1 

    Background: Use of aspirin after diagnosis of colon cancer has been associated with improved survival. Identification of cancer subtypes that respond to aspirin treatment may help develop personalized treatment regimens. The aim of this study was to investigate the influence of BRAF and KRAS...

  • Phenotypic heterogeneity in hereditary non-polyposis colorectal cancer: identical germline mutations associated with variable tumour morphology and immunohistochemical expression. Halvarsson, Britta; Müller, Wolfram; Planck, Maria; Benoni, Anna Clara; Mangell, Peter; Ottosson, Johan; Hallén, Magnus; Isinger, Anna; Nilbert, Mef // Journal of Clinical Pathology;Jul2007, Vol. 60 Issue 7, p781 

    Background: Hereditary non-polyposis colorectal cancer (HNPCC) is associated with high risks for colorectal and endometrial cancer, young age at onset and an increased risk of multiple primary tumours. Colorectal cancer in HNPCC is characterised by poor tumour differentiation, an expanding...

  • Prevalence of Pathological Germline Mutations of hMLH1 and hMSH2 Genes in Colorectal Cancer. Li, Dandan; Hu, Fulan; Wang, Fan; Cui, Binbin; Dong, Xinshu; Zhang, Wencui; Lin, Chunqing; Li, Xia; Wang, Da; Zhao, Yashuang // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Abstract The prevalence of pathological germline mutations in colorectal cancer has been widely studied, as germline mutations in the DNA mismatch repair genes hMLH1 and hMSH2 confer a high risk of colorectal cancer. However, because the sample size and population of previous studies are very...

  • Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation. Xue-Lian Pang; Qiao-Xin Li; Zhi-Ping Ma; Yi Shi; Yu-Qing Ma; Xin-Xia Li; Wen-Li Cui; Wei Zhang // OncoTargets & Therapy;May2017, Vol. 10, p2645 

    The KRAS gene mutation is involved in several types of tumors. However, the potential role of the KRAS mutation in human primary and paired metastatic colorectal cancer (CRC) among different nationalities is poorly understood. In the present study, we assessed the relationship between KRAS...

  • Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. Sjursen, Wenche; Haukanes, Bjørn Ivar; Grindedal, Eli Marie; Aarset, Harald; Stormorken, Astrid; Engebretsen, Lars F.; Jonsrud, Christoffer; Bjørnevoll, Inga; Andresen, Per Arne; Ariansen, Sarah; Lavik, Liss Anne S.; Gilde, Bodil; Bowitz-Lothe, Inger Marie; Mæhle, Lovise; Møller, Pål // Journal of Medical Genetics;Sep2010, Vol. 47 Issue 9, p1 

    Background Reported prevalence, penetrance and expression of deleterious mutations in the mismatch repair (MMR) genes, MLH1, MSH2, MSH6 and PMS2, may reflect differences in the clinical criteria used to select families for DNA testing. The authors have previously reported that clinical criteria...

  • Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC. Di Fiore, F.; Charbonnier, F.; Martin, C.; Frerot, S.; Olschwang, S.; Wang, Q.; Boisson, C.; Buisine, M.-P.; Nilbert, M.; Lindblom, A.; Frebourg, T. // Journal of Medical Genetics;Jan2004, Vol. 41 Issue 1, p18 

    Points out that in hereditary non-polyposis colorectal cancer (HNPCC), point mutations of MSH2, MLH1 or MSH6 are detected in approximately half of the families involved, which therefore fulfill the Amsterdam criteria (AMS). Analysis of MSH2 in 120 AMS+ and 212 AMS- HNPCC families without MSH2...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics